Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic Alix School of Medicine and the Mayo Clinic Medical Scientist Training Program-Rochester, Rochester, MN, USA.
Department of Physical Medicine and Rehabilitation, Rehabilitation Medicine Research Center, Rochester, MN, USA.
Spinal Cord Ser Cases. 2021 Feb 3;7(1):8. doi: 10.1038/s41394-020-00378-y.
We completed retrospective analysis of statin use in individuals with neurologically significant spinal cord injury in a historical cohort study.
Our objective was to establish the prevalence of cholesterol-lowering agent use following spinal cord injury (SCI) and to determine the impact on recovery of motor function.
Patients enrolled in the Rochester Epidemiology Project in Olmsted County, Minnesota, USA from 2005 to 2018 were included in analysis.
Exclusion criteria: age <18, comorbid neurological disease, prior neurological deficit, nontraumatic injury, survival <1 year, or lack of motor deficit. Demographics and cholesterol-lowering agent use in 83 individuals meeting all criteria were recorded. A total of 68/83 individuals were then assessed for change in function over the first 2 months after injury using the ISNCSCI motor subscore. Statistical comparison between control and statin groups was done by two-sided Chi-squared test or two-tailed Student's t test. Generalized regression was performed to assess associations between independent variables and functional outcome.
30% of individuals with SCI had a prescription for a cholesterol-lowering agent. No significant differences were observed in severity of injury or demographic composition between groups. The change in motor subscore was reduced in the statin group compared to controls (p = 0.03, Mann-Whitney). Both severity of injury and statin were significant predictors of reduced motor recovery (p = 0.001, and p = 0.04, respectively).
Both severity of SCI and statins were significant predictors of reduced motor recovery. Additional investigation is needed to address potential impact of statin-therapy in the context of CNS injury and repair.
我们在一项历史性队列研究中对有神经意义的脊髓损伤患者进行了他汀类药物使用的回顾性分析。
我们的目的是确定脊髓损伤（SCI）后使用降胆固醇药物的患病率，并确定其对运动功能恢复的影响。
在美国明尼苏达州奥姆斯特德县的罗切斯特流行病学项目中，从 2005 年到 2018 年招募的患者被纳入分析。
排除标准：年龄<18 岁、合并神经系统疾病、既往神经功能缺损、非创伤性损伤、生存时间<1 年或缺乏运动功能缺损。记录符合所有标准的 83 名患者的人口统计学数据和降胆固醇药物使用情况。然后，共有 68/83 名患者使用 ISNCSCI 运动子评分评估损伤后前 2 个月功能的变化。通过双侧卡方检验或双尾学生 t 检验对对照组和他汀组进行统计学比较。采用广义回归分析评估独立变量与功能结果之间的关系。
30%的 SCI 患者有降胆固醇药物处方。两组间损伤严重程度或人口统计学构成无显著差异。与对照组相比，他汀组的运动子评分变化较小（p=0.03，Mann-Whitney）。损伤严重程度和他汀类药物均是运动恢复减少的显著预测因素（p=0.001 和 p=0.04）。
SCI 的严重程度和他汀类药物均是运动恢复减少的显著预测因素。需要进一步研究，以确定他汀类药物治疗在中枢神经系统损伤和修复背景下的潜在影响。
